JNJ vs ABT
By Alex · Tickerpine
Johnson & Johnson vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABT |
|---|---|---|
| Price | $260.86 | $110.91 |
| Market cap | $628.65B | $191.92B |
| P/E ratio | 30.3 | 35.4 |
| ROE | 25.74% | 10.58% |
| Profit margin | 21.48% | 11.65% |
| Revenue growth | 6.60% | 13.00% |
| Dividend yield | 2.05% | 2.27% |
| Beta | 0.23 | 0.58 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABT in plain English
- JNJ is the bigger company — about 3.3× the market cap of ABT.
- JNJ is cheaper on earnings (P/E 30.3 vs 35.4).
- JNJ earns a higher return on equity (26% vs 11%).
- ABT is growing revenue faster (13% vs 7%).
- ABT has the higher dividend yield (2.27% vs 2.05%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.